Dr Carbone talks with ecancer at the Best of ASCO 2017 meeting in Miami about the developments of targeted therapies for EGFR and ALK mutations in advanced lung cancer patients. He goes on to discuss the new drugs that have been yielding improved efficacy...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uIh30w
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. ...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Abstract The quantitative evaluation of Social Science and Humanities (SSH) and the investigation of the existing similarities between SSH...
-
Related Articles Modulation of the Tumor Microenvironment by Epstein-Barr virus Latent Membrane Protein-1 in Nasopharyngeal Carcinoma....
-
Publication date: Available online 10 March 2018 Source: Radiotherapy and Oncology Author(s): Igor Shuryak, Eric J. Hall, David J. Bre...
-
Sporadic Salmonella outbreaks with varying clinical presentations have been on the rise in various parts of Uganda. The sources of outbreaks...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου